Tarsus Pharmaceuticals, Inc. (TARS) Tops Q3 EPS by 7c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q3 EPS of ($1.28), $0.07 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $399.6 thousand.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Micron Technology (MU) PT Raised to $1,280 at Baird
• Lonza Group (LONN:SW) (LZAGY) PT Raised to CHF720 at RBC Capital